Introduction: Regulatory requirements mandate that new drugs for treatment of patients with
Results: Thirty-six articles met the inclusion criteria encompassing 11 pooled analyses, 17 meta-analyses, and eight RCTs (including secondary analyses). Over the short term (up to 4 years), patients with T2DM exposed to a DPP-4 inhibitor or GLP-1 receptor agonist were not at increased risk for MACE (or its component endpoints) compared with those who received comparator agents. Two meta-analyses showed a significant reduction in the incidence of MACE associated with DPP-4 inhibitor therapy as a drug class, but this beneficial effect was not observed in other meta-analyses that included large RCT CV outcome studies. In four RCTs that evaluated alogliptin, saxagliptin, sitagliptin, or lixisenatide, there was no overall increased risk for MACE relative to placebo in T2DM patients at high risk for CV events or with established CV disease, although there was an increased rate of hospitalization for heart failure associated with saxagliptin. A fifth RCT showed that liraglutide reduced MACE risk by 13% versus placebo.
Conclusion:
Overall, incretin therapy does not appear to increase risk for MACE in the short term.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) significantly increases risk for cardiovascular (CV) disease [1] .
Strategies for the management of CV risk factors are therefore essential to reduce CV morbidity and mortality associated with T2DM [1, 2] .
While clinical trials have provided some evidence that intensive glucose control in patients with T2DM may reduce risk for myocardial infarction (MI) and other major adverse cardiac events (MACE), this is not the case for all-cause mortality [3, 4] . The attendant heightened risk for severe hypoglycemia with intensive glucose-lowering treatment has been postulated to be a significant counterbalance to CV benefit [5] . Indeed, hypoglycemia and other undesired adverse events (AEs) associated with glucose-lowering drugs may be especially deleterious in older, more frail patients with multiple comorbidities [4] . Therefore, while stringent glycated hemoglobin (HbA1c) targets may be appropriate in some patients with T2DM, comprehensive care is increasingly regarded as requiring an individualized approach that includes treatment of all CV risk factors, not just hyperglycemia [1] . Drugs with a good tolerability profile that do not induce hypoglycemia may be compatible with strict glycemic targets even in frail patients.
The two classes of incretin-based therapies, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, can achieve reductions in HbA1c without substantive risk for hypoglycemia [1] .
As the use of these drugs in the management of T2DM has increased [1] , so too has interest in their potential capacity to modify CV risk, either detrimentally or beneficially.
Following concerns over the cardiac safety of rosiglitazone and other antidiabetic drugs in 2008 [6] , current regulatory guidance now requires that new drugs for the treatment of patients with T2DM must withstand long-term and large-scale assessment of CV safety [7] . The
United States Food and Drug Administration (US FDA) may approve an antidiabetic agent if integrated analysis of completed studies demonstrates that its upper 95% confidence interval (CI) limit for the estimated risk ratio (RR) for MACE is less than 1.3 versus comparator. If, however, the upper bound is between 1.3 and 1.8, sponsors must subsequently demonstrate CV safety in post-marketing CV outcomes trials [7] .
Preclinical data and mechanistic studies of DPP-4 inhibitors suggest possible additional nonglycemic beneficial actions on blood vessels and the heart, via both GLP-1-dependent and GLP-1-independent effects [8, 9] . Positive effects of DPP-4 inhibitors on the myocardium have also been described in patients with ischemic heart disease [8] . In patients with T2DM, DPP-4 inhibitors may improve total cholesterol and triglyceride levels [10] , reduce inflammatory markers, oxidative stress, and platelet aggregation, improve endothelial function [8, 9] , and increase circulating endothelial progenitor cells possibly promoting vascular repair [11] . In addition, DPP-4 inhibitors are weight neutral [8] .
Likewise, GLP-1 receptor agonists exert pleiotropic effects on the CV system beyond glycemic control. Overall, GLP-1 receptor agonists have a beneficial effect on traditional CV risk factors [12] , and reduce body weight in overweight or obese patients [13, 14] .
Treatment with GLP-1 receptor agonists in patients with T2DM is associated with a reduction in blood pressure, which precedes weight loss [15] . Furthermore, longer-term studies have also reported some improvements in lipid profile [16] , which could be the consequence of body weight reduction. It has been suggested that the direct stimulation of GLP-1 receptors in the vasculature and myocardium could produce further benefits on CV risk [17] . Conversely, some clinical trial data indicate that treatment with GLP-1 receptor agonists can produce a modest increase in heart rate [18] , which may potentially be associated with a higher CV risk [19] .
By conducting a systematic literature review of integrated analyses and randomized controlled studies specifically designed to assess MACE, we have further examined the relationship between incretin therapies and CV risk in patients with T2DM.
METHODS
This systematic review is reported in line with the criteria stipulated in the PRISMA statement [20] . To identify published clinical data on the CV safety of incretin-based therapies in T2DM, we conducted searches of the US National OR ''integrated analysis'' OR ''systematic review'' OR ''systematic assessment'' OR ''indirect comparison''). The authors screened the title and abstract of each retrieved article for relevance following which full-text articles were obtained and reviewed qualitatively for final inclusion and assessment. Articles solely reporting data on surrogate CV endpoints (e.g., plasma lipids and blood pressure) were excluded. Articles reporting analyses with significant overlap (e.g., updated meta-analyses including the same randomized controlled trials) were excluded. In the case of overlap, the paper reporting the largest dataset was included. For the purpose of this review, a pooled analysis was defined as analysis of combined study data without weighting (i.e., as if the data were derived from a single sample) and a meta-analysis was defined as an analysis of combined study data after data from each study had undergone weighting.
Second, we searched for randomized controlled trials using Boolean logic and the aforementioned drug terms combined with the term ''cardiovascular'' and the terms ''randomized OR randomised OR randomly''. Returned articles were reviewed qualitatively.
To qualify for inclusion, only randomized controlled trials reporting CV outcomes as the primary endpoint were selected. Duplicate articles (i.e., articles reporting the same trial) were excluded. 
RESULTS

Literature Review
Regarding meta-analyses of trial-level data and pooled analyses of patient-level data, searches yielded 109 articles, consisting of 74 articles concerning DPP-4 inhibitors and 36 articles concerning GLP-1 receptor agonists (one meta-analysis of trial-level incretin therapy data was identified in both searches) (Fig. 1a) .
On the basis of the article abstracts, 71 articles were dismissed primarily because an integrated analysis of randomized controlled trial data or CV endpoint data was not reported. Thus, 38 full-text articles were retrieved and further reviewed for eligibility (Table 1) , after which 28 articles met inclusion criteria and were assessed further ( Table 2) .
Eight of 142 citations were identified in relation to randomized controlled trials reporting CV outcomes as a primary endpoint, four of which concerned DPP-4 inhibitors and one which concerned a GLP-1 receptor agonist (Fig. 1b) .
CV Risk of DPP-4 Inhibitors
Pooled Analyses Features Of 11 pooled analyses of individual gliptins that were assessed for eligibility, six were assessed further, including two analyses of linagliptin [21, 22] , and one each for sitagliptin [23] , saxagliptin [24] , vildagliptin [25] , and alogliptin [26] . Numbers, incidences, and RRs of MACE associated with linagliptin and sitagliptin were compared versus placebo, active comparators, and placebo and active comparators combined [21] [22] [23] , whereas the CV safety profiles of saxagliptin, vildagliptin, and alogliptin were evaluated relative to all comparators combined only [24] [25] [26] . One study by Lehrke et al. of linagliptin versus placebo included patient-level data pertaining to CV AEs that were matched with respect to background therapy [22] , whereas the other studies evaluated the MACE profile of DPP-4 inhibitors versus control without regard for concomitant antidiabetic background therapy [21, [23] [24] [25] [26] .
Sample size was largest for the pooled analysis of vildagliptin CV safety (n = 17,446) and lowest for the pooled analysis of alogliptin CV safety (n = 6028) ( Table 3) . Average follow-up time was less than 2 years across all analyses. Although the definitions of MACE utilized in the saxagliptin, linagliptin, vildagliptin, and alogliptin pooled analyses of composite endpoints did vary, they were broadly similar, encompassing CV death, MI, ACS, and stroke. The linagliptin pooled analysis of MACE by Rosenstock et al. was the only analysis to include hospitalization for unstable angina pectoris (UAP) in the composite endpoint [21] , while the saxagliptin pooled analysis included ischemic events as an additional MACE component [24] . The examination of MACE and CV death in two pooled analyses of linagliptin and alogliptin were prespecified [21, 26] , whereas these endpoints were evaluated post hoc for the other DPP-4 inhibitor analyses (Table 2) , which potentially introduces bias and reduces the reliability of the data. The pooled analysis of sitagliptin was further limited in that it included a very broad MACE composite (Table 2) .
MACE Incidence Rates Variable definitions
for MACE only allow exposure-adjusted incidence rates to be compared within and not between pooled analyses. Even so, Table 3 shows that exposure-adjusted incidence rates [25] . Exposure-adjusted CV death ranged from 0.24 to 0.34 per 100 patient-years for linagliptin [21] , sitagliptin [23] , alogliptin [26] , saxagliptin [24] , and vildagliptin [25] .
MACE Risk Across the various pooled analyses, none of the DPP-4 inhibitor 20, 40 , or 100 mg/day was administered in one phase 2b study h One of the 22 studies tested linagliptin 2.5 mg/day i Nearly two-thirds of patients received treatment for at least 24 weeks [22] j Mean duration of exposure for vildagliptin versus comparators [25] k Did not include data from EXAMINE [28] l Range of medians for studies of each DPP-4 inhibitor or GLP-1 receptor agonist m Did not include data from LEADER [57] [21, 23] . In the comparison of linagliptin with placebo, the exposure-adjusted incidence rates for MACE were 1.49 and 1.64
per 100 patient-years, respectively, yielding an overall hazard ratio (HR) of 1.09 (95% CI 0.68-1.75) [21] , while the corresponding rates for sitagliptin versus placebo were 0.80 and 0.76 per 100 patient-years, respectively (incidence rate ratio 1.01; 95% CI 0.55-1.86) [23] .
Subgroup analyses further showed that the magnitude of the adjudicated MACE risk associated with linagliptin and vildagliptin 50 mg once and twice daily versus total comparators was not affected by age, sex, or high CV disease risk status [21, 25] . Race, use of rescue therapy, occurrence of hypoglycemia, renal function, microalbuminuria, or use of background medication (insulin and/or metformin) were also factors deemed not to impact the magnitude of adjudicated MACE risk associated with linagliptin versus total comparators [21] . Subgroup analyses of adjudicated MACE for saxagliptin suggested that the 2.5 mg daily dosage regimen (incidence rate ratio 0.33; 95% CI 0.10-0.89) but not the 5 mg daily dosage regimen (incidence rate ratio 0.74; 95% CI 0.40-1.36) had a lower MACE risk relative to all comparators [24] . Any saxagliptin dosage adjunctive to metformin was not associated with increased risk for MACE relative to control (incidence rate ratio 0.93; 95% CI 0.44-1.99) [24] . Limited data from three studies showed that sitagliptin was associated with a lower incidence and risk of MACE than a sulfonylurea (exposure-adjusted incidence rate 0.00 per 100 patient-years with sitagliptin versus 0.86 with sulfonylurea: incidence rate ratio 0.00; 95% CI 0.00-0.31) [23] .
MACE Components Although risks for
individual components of the composite MACE endpoints were not consistently reported across the pooled analyses, it was apparent that the risks for individual CV components were not increased with Fig. 2 Risk of a MACE: a pooled analyses of patient-level data for specific DPP-4 inhibitors, b meta-analyses of trial-level data for specific DPP-4 inhibitors, and c meta-analyses of trial-level data for DPP-4 inhibitors as a drug class. MACEs were defined differently in each analysis (see Table 2 ). CI confidence interval, DPP-4 dipeptidyl peptidase-4, HR hazard ratio, OR odds ratio, RR risk ratio. [21, 24, 25] , and that the risk for CV-related death was not heightened by sitagliptin relative to control (Table 4) [23] . There was some evidence suggesting that linagliptin was associated with a reduced risk Of the two meta-analyses that described overall CV safety of individual DPP-4 inhibitors as a primary endpoint [29, 30] , one was restricted to monotherapy studies of 18 trials [30] , whereas the other was extended to studies in which DPP-4 inhibitors were administered in association with other glucose-lowering agents, provided that concurrent therapies were the same in all treatment groups [29] . All of the studies included in the monotherapy analysis [30] were also included in the larger analysis of all available studies [29] .
MACE Risk
The larger of the two meta-analyses assessing overall CV safety of individual DPP-4 inhibitors included 70 trials: nine trials of linagliptin, 13 trials of saxagliptin, 27 trials of sitagliptin, 16 trials of vildagliptin, and five trials of alogliptin [29] . Sixty-three of these 70 trials reported MACE, and enrolled a total of 40,071 patients, including 23,562 assigned to treatment with one of the five DPP-4 inhibitors and 16,509 assigned to control treatment [29] . With a total of 263 MACE attributed to DPP-4 inhibitors, the exposure-adjusted incidence rate of 1.12 events per 100 patient-years was not dissimilar to that of the patient-level data in the aforementioned pooled analyses (Table 3) .
Overall, the results of this meta-analysis were in agreement with the pooled analyses in that no DPP-4 inhibitor was associated with a statistically significant increased risk for MACE as their 95% CIs crossed unity (Fig. 2b) [29] .
More specifically, there was a general trend of the base-case point estimates towards a MACE risk reduction in patients assigned to any of the five DPP-4 inhibitors relative to control, although these reductions only reached statistical significance with saxagliptin and vildagliptin (Fig. 2b) [29] . Corresponding findings from the smaller meta-analysis of DPP-4 inhibitor monotherapy studies were similar in that there was no suggestion of statistically significant increased risk for MACE with DPP-4 inhibitors but a statistically significantly reduced MACE risk was detected with sitagliptin ( Fig. 2b) [30] ; however, the latter finding has subsequently been refuted by the TECOS randomized, placebo-controlled study, which demonstrated that sitagliptin neither increased nor decreased MACE risk (see below) [44] .
A third meta-analysis tested the association between individual DPP-4 inhibitors and risk for the composite MACE endpoint as a secondary objective [33] . By including EXAMINE and SAVOR-TIMI 53 [28, 43] this meta-analysis was unevenly weighted since these phase 4 trials were characterized by very large sample sizes and prolonged follow-up relative to the other phase 2/3 trials included in the analysis [33] . Furthermore, the clinical characteristics of the patients who participated in EXAMINE and SAVOR-TIMI 53 were considerably different from the populations of the other included trials (i.e., patients were at higher risk for MACE) [28, 43] . Even so, no statistically significant increased risk for MACE was detected with any DPP-4 inhibitor in this meta-analysis (Fig. 2b) , and the available data suggested that linagliptin could be associated with a reduced risk for MACE [33] .
Two meta-analyses suggested a significant reduction in the incidence of MACE associated with DPP-4 inhibitor therapy as a drug class, with an estimated odds ratio (OR) of 0.48 (95% CI 0.31-0.75) for the meta-analysis of monotherapy studies [30] and 0.71 (95% CI 0.59-0.86) for the larger meta-analysis of all available studies (Fig. 2c) [29] . However, in the meta-analysis conducted by Agarwal et al. this statistical advantage in favor of DPP-4 inhibitor therapy was annulled when EXAMINE and SAVOR-TIMI 53 data were included (OR 0.95; 95% CI 0.86-1.04) [33] . No change in effect size was observed when the ORs were recalculated using a continuity correction to avoid distortions because of the exclusion of trials with zero events [29, 30] , or by use of a random effects model instead of a fixed effects model [33] . Subgroup analysis of the meta-analysis of monotherapy studies revealed that studies with a duration of at least 52 weeks demonstrated a lower risk for MACE with DPP-4 inhibitor therapy than control (RR 0.37; 95% CI 0.21-0.63; P = 0.0003), which was not the case in shorter-term studies (RR 0.78; 95% CI 0.38-1.60; P = 0.50) [30] . Meta-regression revealed no influence of sex, diabetes duration, or HbA1c level upon the pooled OR for MACE in the meta-analysis by Agarwal et al. [33] .
In the larger meta-analysis performed by Monami et al., risk of MACE with DPP-4 inhibitor therapy was 28% lower when compared with placebo based on 38 studies with at least one event (OR 0.72; 95% CI 0.56-0.92; P = 0.01) [29] Fixed and random effects meta-analyses of three phase 4 prospective CV outcome studies found no evidence for an increased risk of MACE associated with alogliptin, saxagliptin, and sitagliptin as a class versus placebo in high-risk patients with T2DM (fixed and random effects model: RR 0.99; 95% CI 0.93-1.06 [42] ; random effects model: OR 0.99; 95% CI 0.92-1.06 [39] ). However, the scientific validity of pooling clinical trial data from distinct CV risk populations must be taken into consideration when interpreting these results.
Twelve of the 14 meta-analyses reported individual DPP-4 inhibitor data and DPP-4 inhibitor data as a drug class on the components of MACE composite endpoints [29, 30, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . In general, there was no class effect on the risk for the three most commonly used MACE components (CV death, MI, and stroke), as well as for other MACE components ( Table 4 ). The drug class was associated with lower risk for MI in two meta-analyses [29, 36] , although this association was lost over the long term (i.e., more than 29 weeks' treatment) in the meta-analysis that included EXAMINE and SAVOR-TIMI 53 data (see below) [36] .
Ninety-five percent CIs of pooled ORs/RRs for death, CV death, MI, and stroke included the value 1 when the data were stratified by individual DPP-4 inhibitor therapy, with the exception of stroke risk with linagliptin (OR 0.45; 95% CI 0.23-0.89 [33] ; RR 0.29; 95% CI 0.13-0.65; P = 0.003 [36] ) and vildagliptin (OR 0.23; 95% CI 0.07-0.71 [33] ; RR 0.30; 95% CI 0.10-0.92; P = 0.035 [36] ; and OR 0.26; 95% CI 0.08-0.84 [41] ). Vildagliptin was also associated with significant reduction in the risk of MI (RR 0.35; 95% CI 0.17-0.72; P = 0.004) [36] . There was a higher risk for HF associated with DPP-4 inhibitors as a drug class in a meta-analysis that focused on this outcome as a primary endpoint [34] , as well as a 16% increased HF risk in two other meta-analyses that included EXAMINE (alogliptin) and SAVOR-TIMI 53 (saxagliptin) data [35, 36] . A meta-analysis of EXAMINE and SAVOR-TIMI 53 data exclusively indicated that DPP-4 inhibitor therapy with either alogliptin or saxagliptin was associated with a 25% increased risk for HF relative to standard care with glucose or weight management (RR 1.25; 95% CI 1.08-1.45; P = 0.0033) [37] , although this risk became nonsignificant in four other meta-analyses also featuring TECOS data (sitagliptin versus placebo) (RR 1.12; 95% CI 1.00-1.25 [42] ; OR 1.14; 95% CI 0.97-1.34 [39] ; RR 1.116; 95% CI 0.995-1.228 [38] ; OR 0.97; 95% CI 0.61-1.56 [40] ; Table 4 ). When analyzed individually, only saxagliptin was associated with increased risk for HF (RR 1.215; 95% CI 1.028-1.437; P = 0.022 [38] ; OR 1.23; 95% CI 1.03-1.56 [41] ), which is likely driven by an increased risk in patients at high CV risk (RR 1.257; 95% CI 1.060-1.491; P = 0.009) rather than low CV risk (RR 0.537; 95% CI 0.232-1.245; P = 0.148) [38] .
Randomized Controlled Trial Data
We identified one primary article and one secondary article for the Examination of Cardiovascular Outcomes with Alogliptin interaction P value 0.67) patients who received saxagliptin and placebo [47] . The increased risk of HF-associated hospitalization with saxagliptin relative to placebo was similar regardless of age group [47] . (Table 5 ) [44] .
CV Risk of GLP-1 Receptor Agonists
Pooled Analyses
Features Of nine articles on GLP-1 receptor agonists identified from our literature search, five were drug-specific pooled analyses-one each for liraglutide [50] , exenatide twice daily [51] , taspoglutide [52] , albiglutide [53] , and dulaglutide [54] ( Table 2) . Excluding taspoglutide (since development has been suspended), the sample size was largest for the pooled analysis of liraglutide CV safety (n = 6638) and smallest for that of exenatide (n = 3945) ( Table 3 ). These analyses assessed Table 5 continued LEADER: Patients with T2DM who were at high risk for CV events [57] Endpoint liraglutide [50] , with placebo and insulin combined for exenatide [51] , and with placebo and active comparators combined for albiglutide [53] and dulaglutide [54] . The authors of the exenatide study acknowledge that pooling the placebo group with a single active-comparator group was a necessary limitation to provide greater statistical power [51] . Adjudicated MACEs were evaluated on a post hoc basis in the liraglutide and exenatide analyses but were prespecified in the albiglutide and dulaglutide analyses [50, 51, 53, 54] . The MACE definitions were broadly similar except that the exenatide pooled analysis included ACS and revascularization procedures in addition to CV death, stroke, and MI [51] . Technically, time to first MACE was a secondary endpoint in the albiglutide pooled analysis, as the primary endpoint was time to first MACE or hospital admission for UAP [53] . [53] .
MACE Risk
c Secondary MACE composite endpoint, which included all relevant CV AEs [i.e., all terms of the primary MACE endpoint plus terms for arrhythmia, heart failure (with or without hospitalization), and mechanical-related events] [51] associated with albiglutide exceeded 1.3 regardless of whether the control arm was all comparators, placebo, or active comparators [53] .
Aside from a protective effect of dulaglutide regarding nonfatal MI, there was no effect of albiglutide and dulaglutide on the risk for MACE components in the two pooled analyses that reported such data (Table 4) [53, 54] .
Meta-analyses
Features We identified four meta-analyses of GLP-1 receptor agonists for assessment (Table 2) [12, 41, 55, 56] . One meta-analysis of trial-level data reported comparisons between GLP-1 receptor agonists and non-GLP-1 receptor agonists [12] . Composite data were taken from 37 trials of which 33, 29, 29, 33 , and 31 reported on MACE, MI, stroke, all-cause mortality, and CV mortality, respectively, and 25 reported at least one event [12] . Most of the 37 trials pertained to exenatide (n = 21 for exenatide twice daily; n = 5 for exenatide once daily), with eight trials of liraglutide, two of albiglutide, and one of taspoglutide. These studies enrolled a total of 15,398 patients at low risk for a MACE, including 8619 assigned to treatment with a GLP-1 receptor agonist and 6779 assigned to a comparator (Table 3 ) [12] . The definition of MACE was the same as that reported by Monami et al. in a large meta-analysis of DPP-4 inhibitor therapy [12, 29] . (Fig. 3) [12] . Subgroup analysis found that GLP-1 receptor agonists could be associated with a significant reduction in the incidence of (Table 4) .
A second meta-analysis was a pairwise analysis of 15,883 patients who participated in 45 randomized controlled trials [55] . It was designed to reveal any significant differences between GLP-1 receptor agonists and placebo, active comparators, or another GLP-1 agent on CV safety (i.e., CV mortality, ischemic heart disease, nonfatal HF, and stroke). [55] . Table 4 shows that the GLP-1 receptor agonist drug class and its members were not associated with increasing risk of MACE components, including heart failure, on the basis of results of three meta-analyses [12, 41, 56] , although there was evidence associating exenatide with increased risk of arrhythmia (OR 2.83; 95% CI 1.06-7.57) [41] .
Randomized Controlled Trial Data
We identified one primary article each for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial [48] Table 5 ).
Superiority of lixisenatide to placebo was also not demonstrated since the upper boundary of the 95% CI was not less than 1.0 (P = 0.81).
There was no statistical separation between the groups with respect to rate of hospitalization for HF (HR 0.96; 95% CI 0.75-1.23; P = 0.75 for superiority) [48] .
LEADER was a randomized, double-blind, noninferiority trial of 9340 T2DM patients who had a higher baseline HbA1c level than the other CV outcome trials (mean, 8.7%) [57] . The only potential CV safety signal raised to date is the increased rate of hospitalization for HF associated with saxagliptin treatment in SAVOR-TIMI 53 [43] . While no such finding was detected in the pooled analysis of saxagliptin trials (HR 0.55; 95% CI 0.27-1.12) [24] , three meta-analyses of DPP-4 inhibitors did indicate that this drug class or certain members of it may slightly increase risk for HF. Of course, a major caveat would be that the findings of the meta-analyses are heavily influenced by inclusion of SAVOR-TIMI 53, which was responsible for a large proportion of the investigator-reported events [34] [35] [36] .
There was no significantly increased risk for HF reported for alogliptin in EXAMINE [63] , sitagliptin in TECOS [44] , lixisenatide in ELIXA [48] , or liraglutide in LEADER [57] . It is possible that a risk of HF associated with DPP-4 inhibitors is present in certain subpopulations of patients, but this requires further investigation.
Our systematic review has a number of limitations that should be considered when interpreting the findings. Methodologically, pooled analyses of patient-level data are more sensitive than meta-analyses of trial-level data because the former contain a greater amount of information (e.g., time to event) compared with the latter, which only capture whether an event has occurred during the evaluated trials. This difference is particularly relevant when considering longer-term trials, but can also affect short-term studies, such as those included in the present integrated analyses.
Furthermore, meta-analyses that exclude trials with no reported events can produce further, small distortions in overall event rates. Some of the trials of individual DPP-4 inhibitors that are indirectly captured in the present analysis did not adequately report CV events and were therefore excluded from two of the meta-analyses [29, 30] , while still included in the pooled analyses of individual gliptins [21, 24, 64] . The updated vildagliptin pooled analysis [25] also included many more studies (37 versus 16 studies) that did not feature in the meta-analysis performed by Monami et al. [29] . When assessing data across individual pooled analyses, it is important to bear in mind that differences in event rates could arise from diversities in case mix, definition and adjudication of events, choice of comparators, and methods of analysis, rather than differences in the actual therapeutic effects across molecules of the class. Finally, the extent of publication bias in this systematic review is likely minimal given that reporting MACE in randomized controlled trials of new antidiabetic agents is mandatory. There are also several inherent study design limitations to the CV outcome trials. Firstly, study participants were followed for a reasonably short period of time, and, therefore, benefits and risks of longer-term treatment with the various incretin therapies with respect to CV outcomes requires further determination. For instance, the benefit of improved glycemic control in reducing the risk of MI in UKPDS did not become statistically significant until 10 years of follow-up after the initial treatment period [3] . 43, 44, 48, 57] . However, none of the studies were designed to detect a difference in glycemic control between treatment arms, and in SAVOR-TIMI 53, TECOS, and LEADER, background glucose-lowering treatment was intensified more in the placebo group than in the active treatment groups [43, 44, 57] . Finally, in EXAMINE and ELIXA [28, 48] , patients were treated with incretin therapy approximately 6 weeks and 10 weeks post-ACS, respectively, and it is not known if initiating treatment earlier than 1 month would have had beneficial effects on CV outcomes.
Several other large-scale clinical trials intended to assess CV outcomes associated with incretin therapy in T2DM are ongoing. 
